What disease does sotorasib treat?

Sotorasib is a new anti-cancer drug mainly used to treat advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation. Non-small cell lung cancer is a major type of lung cancer, and KRAS G12C mutation is a common cancer driver gene mutation, which is particularly closely related to the occurrence of advanced non-small cell lung cancer.

KRAS G12C mutation causes abnormal activation of cell signaling pathways, promoting abnormal proliferation and survival of cancer cells. By specifically interfering with the KRAS G12C mutation, sotoracib can block this abnormal signaling pathway, thereby inhibiting the growth and spread of tumor cells. Compared with traditional cancer treatments, sotoraxib is more precisely targeted, thus minimizing its impact on normal cells and reducing treatment-related adverse reactions.

The development of this drug represents a major breakthrough in the field of oncology treatment, because The KRAS G12C mutation has long been considered a difficult-to-treat cancer mutation. The launch of sotorasiib fills a gap in this area and provides a new treatment option for those patients with this specific mutation.

However, it is important to note that sotorasiib is not suitable for all patients with non-small cell lung cancer, but only for those carrying the KRAS G12C mutation. When using this drug, doctors need to use genetic testing to confirm whether the patient is suitable for treatment with sotoraxib to ensure optimal efficacy and safety. Overall, the emergence of sotorasiib provides a new hope for some patients with advanced non-small cell lung cancer and also brings new possibilities to the field of cancer treatment.

The original drug of sotorasibu has not yet been launched in China, so patients cannot purchase it domestically and need to purchase sotorasibu through overseas channels. The price of the original version of sotorasibu in Hong Kong, China, with the specifications of 120mg*240 tablets, is around 8 million, and the price of the European version of the original drug with the same specifications is around 4 million, which is relatively expensive. The cheaper ones are the generic drugs marketed abroad. For example, the price of generic drugs in Laos and Bangladesh is around two to three thousand yuan. The price is relatively cheap, and the ingredients of foreign generic drugs are basically the same as the original drugs.